Advertisement
NuAire
NuAire

Bio Business

» FDA, tuberculosis and cancer

Most Recent

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

1 Comment

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: That Loving Feeling

That Loving Feeling

By | July 1, 2014

There are no FDA-approved drugs to treat low sexual desire in women, but not for lack of trying.

1 Comment

image: Outwitting the Perfect Pathogen

Outwitting the Perfect Pathogen

By | January 1, 2014

Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.

0 Comments

image: How Safe Is Your Medicine Cabinet?

How Safe Is Your Medicine Cabinet?

By | May 1, 2013

After numerous high-profile safety scares, clinicians and regulators push to fix critical weaknesses in the FDA’s monitoring system for approved drugs.

1 Comment

image: The Little Cell That Could

The Little Cell That Could

By | July 1, 2012

Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

1 Comment

image: Make Mine Rare

Make Mine Rare

By | August 1, 2011

With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.

6 Comments

image: Take Two of These

Take Two of These

By | June 22, 2011

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.

3 Comments

Advertisement

Popular Now

  1. Most Earth-like Planet Found
  2. AAAAA Is for Arrested Translation
  3. Four-legged Snake Fossil Found
  4. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

Advertisement
Advertisement